Search results
Showing 136 to 150 of 182 results for pembrolizumab
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Discontinued Reference number: GID-TA10848
In development Reference number: GID-TA11406 Expected publication date: TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Discontinued Reference number: GID-TA10202
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
In development Reference number: GID-TA11008 Expected publication date: TBC
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
This guidance has been updated and replaced by NICE technology appraisal guidance 766.
In development Reference number: GID-TA11345 Expected publication date: TBC
In development Reference number: GID-TA11627 Expected publication date: TBC
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
In development Reference number: GID-TA11556 Expected publication date: TBC